Radiation-induced signaling pathways that promote cancer cell survival (Review)

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 1813-1819

  Hein, Ashley L ^a   Ouellete, Michel M ^a   Yan, Ying ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cell cycle checkpoint; Cell survival; DNA repair; Radiation therapy; Signaling pathways

Indexed keywords

CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; TRASTUZUMAB; RADIOSENSITIZING AGENT;

CANCER CELL; CANCER RADIOTHERAPY; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DNA REPAIR; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; APOPTOSIS; CELL TRANSFORMATION; DNA DAMAGE; DRUG EFFECTS; NEOPLASMS; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE;

APOPTOSIS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; HUMANS; NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 84907189603     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2614     Document Type: Review

References (101)

1. P ignon JP, le Maitre A, Maillard E and Bourhis J: Meta-Analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92: 4-14, 2009.
2. Ramnath N, Dilling TJ, Harris LJ, et al: Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest 143: ES314-eS340, 2013.
3. Wilkinson-Ryan I, Binder PS, Pourabolghasem S, et al: Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer. Gynecol Oncol 134: 24-28, 2014.
4. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: A link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002.
5. Milas L, Raju U, Liao Z and Ajani J: Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 32: S78-S81, 2005.
6. Bernier J: Current state-of-Yhe-Art for concurrent chemoradiation. Semin Radiat Oncol 19: 3-10, 2009.
7. Ghiam AF, Spayne J and Lee J: Current challenges and future perspectives of radiotherapy for locally advanced breast cancer. Curr Opin Support Palliat Care 8: 46-52, 2014.
8. Gewirtz DA: Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage. Breast Cancer Res Treat 62: 223-235, 2000.
9. Hawkins AJ, Golding SE, Khalil A and Valerie K: DNA doublestrand break-induced pro-survival signaling. Radiother Oncol 101: 13-17, 2011.
10. Raleigh DR and Haas-Kogan DA: Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Future Oncol 9: 219-233, 2013.
11. Navolanic PM, Steelman LS and McCubrey JA: EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol 22: 237-252, 2003.
12. L inggi B and Carpenter G: ErbB receptors: New insights on mechanisms and biology. Trends Cell Biol 16: 649-656, 2006.
13. Arteaga Carlos L and Engelman Jeffrey A: ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25: 282-303, 2014.
14. Rexer BN and Arteaga CL: Intrinsic and acquired resistance to HER2-Yargeted therapies in HER2 gene-Amplified breast cancer: Mechanisms and clinical implications. Crit Rev Oncog 17: 1-16, 2012.
15. V alerie K, Yacoub A, Hagan MP, et al: Radiation-induced cell signaling: Inside-out and outside-in. Mol Cancer Ther 6: 789-801, 2007.
16. Goldkorn T, Balaban N, Shannon M and Matsukuma K: EGF receptor phosphorylation is affected by ionizing radiation. Biochim Biophys Acta 1358: 289-299, 1997.
17. L ee H-C, An S, Lee H, et al: Activation of epidermal growth factor receptor and its downstream signaling pathway by nitric oxide in response to ionizing radiation. Mol Cancer Res 6: 996-1002, 2008.
18. Kiyozuka M, Akimoto T, Fukutome M, Motegi A and Mitsuhashi N: Radiation-induced dimer formation of EGFR: Implications for the radiosensitizing effect of cetuximab. Anticancer Res 33: 4337-4346, 2013.
19. Y an Y, Hein AL, Greer PM, et al: A novel function of HER2/Neu in the activation of G2/M checkpoint in response to [gamma]-irradiation. Oncogene: June 9, 2014 (Epub ahead of print). doi: 10.1038/onc.2014.167.
20. Meng TC, Fukada T and Tonks NK: Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 9: 387-399, 2002.
21. L each JK, Van Tuyle G, Lin PS, Schmidt-Ullrich R and Mikkelsen RB: Ionizing radiation-induced, mitochondriadependent generation of reactive oxygen/nitrogen. Cancer Res 61: 3894-3901, 2001.
22. Nyati MK, Maheshwari D, Hanasoge S, et al: Radiosensitization by Pan ErbB Inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 10: 691-700, 2004.
23. L iang K, Lu Y, Jin W, Ang KK, Milas L and Fan Z: Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2: 1113-1120, 2003.
24. Geoerger B, Gaspar N, Opolon P, et al: EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer 123: 209-216, 2008.
25. Dittmann K, Mayer C, Fehrenbacher B, et al: Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280: 31182-31189, 2005.
26. Dittmann K, Mayer C and Rodemann HP: Inhibition of radiationinduced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76: 157-161, 2005.
27. Dent P, Yacoub A, Fisher PB, Hagan MP and Grant S: MAPK pathways in radiation responses. Oncogene 22: 5885-5896, 2003.
28. Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC and Persons DL: Cisplatin-induced response of c-jun N-Yerminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol Carcinog 29: 219-228, 2000.
29. Abbott DW and Holt JT: Mitogen-Activated protein kinase kinase 2 activation is essential for progression through the G2/M checkpoint arrest in cells exposed to ionizing radiation. J Biol Chem 274: 2732-2742, 1999.
30. Tang D, Wu D, Hirao A, et al: ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 277: 12710-12717, 2002.
31. Y an Y, Black CP and Cowan KH: Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 26: 4689-4698, 2007.
32. Munshi A and Ramesh R: Mitogen-Activated protein kinases and their role in radiation response. Genes Cancer 4: 401-408, 2013.
33. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J and Rivard N: MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79: 355-369, 2000.
34. Aoudjit F and Vuori K: Matrix attachment regulates Fas-induced apoptosis in endothelial cells: A role for c-flip and implications for anoikis. J Cell Biol 152: 633-643, 2001.
35. Jost M, Huggett TM, Kari C, Boise LH and Rodeck U: Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J Biol Chem 276: 6320-6326, 2001.
36. Bonni A, Brunet A, West AE, Datta SR, Takasu MA and Greenberg ME: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286: 1358-1362, 1999.
37. Clark CJ, McDade DM, O'Shaughnessy CT and Morris BJ: Contrasting roles of neuronal Msk1 and Rsk2 in Bad phosphorylation and feedback regulation of Erk signalling. J Neurochem 102: 1024-1034, 2007.
38. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, et al: ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. Embo J 26: 2856-2867, 2007.
39. Allan LA, Morrice N, Brady S, Magee G, Pathak S and Clarke P R: Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5: 647-654, 2003.
40. Tamamoto T, Ohnishi K, Takahashi A, et al: Correlation between gamma-ray-induced G2 arrest and radioresistance in two human cancer cells. Int J Radiat Oncol Biol Phys 44: 905-909, 1999.
41. Fritz G, Brachetti C and Kaina B: Lovastatin causes sensitization of HeLa cells to ionizing radiation-induced apoptosis by the abrogation of G2 blockage. Int J Radiat Biol 79: 601-610, 2003.
42. Y an Y, Black CP, Cao PT, et al: Gamma-irradiation-induced DNA damage checkpoint activation involves feedback regulation between extracellular signal-regulated kinase 1/2 and BRCA1. Cancer Res 68: 5113-5121, 2008.
43. Y acoub A, McKinstry R, Hinman D, Chung T, Dent P and Hagan MP: Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 159: 439-452, 2003.
44. Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF and Valerie K: Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8: 730-738, 2009.
45. Wei F, Yan J, Tang D, et al: Inhibition of ERK activation enhances the repair of double-stranded breaks via non-homologous end joining by increasing DNA-PKcs activation. Biochim Biophys Acta 1833: 90-100, 2013.
46. Cohen-Armon M: PARP-1 activation in the ERK signaling pathway. Trends Pharmacol Sci 28: 556-560, 2007.
47. Cohen-Armon M, Visochek L, Rozensal D, et al: DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: A link to histone acetylation. Mol Cell 25: 297-308, 2007.
48. Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF and Valerie K: Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 67: 1046-1053, 2007.
49. Y an Y, Greer PM, Cao PT, Kolb RH and Cowan KH: RAC1 GTPase plays an important role in gamma-irradiation induced G2/M checkpoint activation. Breast Cancer Res 14: R60, 2012.
50. S asaoka T, Langlois WJ, Leitner JW, Draznin B and Olefsky JM: The signaling pathway coupling epidermal growth factor receptors to activation of p21ras. J Biol Chem 269: 32621-32625, 1994.
51. Janes PW, Daly RJ, deFazio A and Sutherland RL: Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9: 3601-3608, 1994.
52. Dent P, Reardon DB, Park JS, et al: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-Activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10: 2493-2506, 1999.
53. Hagan M, Wang L, Hanley JR, Park JS and Dent P: Ionizing radiation-induced mitogen-Activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res 153: 371-383, 2000.
54. P olivka J Jr and Janku F: Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142: 164-175, 2014.
55. Y amaguchi H and Wang HG: The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20: 7779-7786, 2001.
56. Gardai SJ, Hildeman DA, Frankel SK, et al: Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem 279: 21085-21095, 2004.
57. Qi XJ, Wildey GM and Howe PH: Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 281: 813-823, 2006.
58. Engström M, Karlsson R and Jönsson J-I: Inactivation of the forkhead transcription factor FoxO3 is essential for PKB-mediated survival of hematopoietic progenitor cells by kit ligand. Exp Hematol 31: 316-323, 2003.
59. Y ang JY, Xia W and Hu MC: Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol 29: 643-648, 2006.
60. Obexer P, Geiger K, Ambros PF, Meister B and Ausserlechner MJ: FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ 14: 534-547, 2007.
61. Jang S-W, Yang S-J, Srinivasan S and Ye K: Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. J Biol Chem 282: 30836-30844, 2007.
62. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-Yhreonine kinase. Nature 401: 82-85, 1999.
63. Dan HC, Sun M, Kaneko S, et al: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279: 5405-5412, 2004.
64. S haw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
65. Fumarola C, Bonelli MA, Petronini PG and Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol 90: 197-207, 2014.
66. Fleckenstein K, Zgonjanin L, Chen L, et al: Temporal onset of hypoxia and oxidative stress after pulmonary irradiation. Int J Radiat Oncol Biol Phys 68: 196-204, 2007.
67. S endoel A and Hengartner MO: Apoptotic cell death under hypoxia. Physiology 29: 168-176, 2014.
68. King TD, Bijur GN and Jope RS: Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3β and attenuated by lithium. Brain Res 919: 106-114, 2001.
69. L oberg RD, Vesely E and Brosius FC: Enhanced glycogen synthase kinase-3β activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. J Biol Chem 277: 41667-41673, 2002.
70. Toulany M, Kehlbach R, Florczak U, et al: Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 7: 1772-1781, 2008.
71. S oltoff SP, Carraway KL III, Prigent SA, Gullick WG and Cantley LC: ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Int J Radiat Biol 14: 3550-3558, 1994.
72. Marone R, Cmiljanovic V, Giese B and Wymann MP: Targeting phosphoinositide 3-kinase -moving towards therapy. Biochim Biophys Acta 1784: 159-185, 2008.
73. Toulany M, Baumann M and Rodemann HP: Stimulated PI3K-AKT signaling mediated through ligand or radiationinduced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res 5: 863-872, 2007.
74. Minjgee M, Toulany M, Kehlbach R, Giehl K and Rodemann HP: K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys 81: 1506-1514, 2011.
75. Toulany M, Lee K-J, Fattah KR, et al: Akt promotes postirradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res 10: 945-957, 2012.
76. S ahlberg SH, Gustafsson AS, Pendekanti PN, Glimelius B and Stenerlow B: The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines. Tumour Biol 35: 3525-3534, 2014.
77. S himura T, Kakuda S, Ochiai Y, Kuwahara Y, Takai Y and Fukumoto M: Targeting the AKT/GSK3β/cyclin D1/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy. Int J Radiat Oncol Biol Phys 80: 540-548, 2011.
78. Kim IA, Bae SS, Fernandes A, et al: Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 65: 7902-7910, 2005.
79. Contessa JN, Hampton J, Lammering G, et al: Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21: 4032-4041, 2002.
80. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
81. S honai T, Adachi M, Sakata K, et al: MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells. Cell Death Differ 9: 963-971, 2002.
82. L ee YJ, Soh JW, Jeoung DI, et al: PKC epsilon-mediated ERK1/2 activation involved in radiation-induced cell death in NIH3T3 cells. Biochim Biophys Acta 1593: 219-229, 2003.
83. Dai X-F, Ding J, Zhang R-G, Ren J-H, Ma C-MC and Wu G: Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway. Int J Radiat Biol 89: 1, 2013.
84. S ancar A, Lindsey-Boltz LA, Unsal-Kacmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39-85, 2004.
85. S mits VA and Medema RH: Checking out the G(2)/M transition. Biochim Biophys Acta 1519: 1-12, 2001.
86. O'Connell MJ and Cimprich KA: G2 damage checkpoints: What is the turn-on? J Cell Sci 118: 1-6, 2005.
87. Chen T, Stephens PA, Middleton FK and Curtin NJ: Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today 17: 194-202, 2012.
88. Kharbanda S, Saleem A, Datta R, Yuan ZM, Weichselbaum R and Kufe D: Ionizing radiation induces rapid tyrosine phosphorylation of p34cdc2. Cancer Res 54: 1412-1414, 1994.
89. Rhind N, Furnari B and Russell P: Cdc2 tyrosine phosphorylation is required for the DNA damage checkpoint in fission yeast. Genes Dev 11: 504-511, 1997.
90. O'Connell MJ, Raleigh JM, Verkade HM and Nurse P: Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. Embo J 16: 545-554, 1997.
91. L undgren K, Walworth N, Booher R, Dembski M, Kirschner M and Beach D: Mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell 64: 1111-1122, 1991.
92. P arker LL, Atherton-Fessler S and Piwnica-Worms H: P107wee1 is a dual-specificity kinase that phosphorylates p34cdc2 on tyrosine 15. Proc Natl Acad Sci US A 89: 2917-2921, 1992.
93. Bulavin DV, Higashimoto Y, Demidenko ZN, et al: Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol 5: 545-551, 2003.
94. Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature 432: 316-323, 2004.
95. Nikjoo H, O'Neill P, Wilson WE and Goodhead DT: Computational approach for determining the spectrum of DNA damage induced by ionizing radiation. Radiat Res 156: 577-583, 2001.
96. Y u H: Typical cell signaling response to ionizing radiation: DNA damage and extranuclear damage. Chin J Cancer Res 24: 83-89, 2012.
97. Ward JF: DNA damage as the cause of ionizing radiationinduced gene activation. Radiat Res 138: S85-S88, 1994.
98. Haddy N, Tartier L, Koscielny S, et al: Repair of ionizing radiation-induced DNA damage and risk of second cancer in childhood cancer survivors. Carcinogenesis: Apr 19, 2014 (Epub ahead of print).
99. Huhn D, Bolck HA and Sartori AA: Targeting DNA doublestrand break signalling and repair: Recent advances in cancer therapy. Swiss Med Wkly 143: W13837, 2013.
100. Hosoya N and Miyagawa K: Targeting DNA damage response in cancer therapy. Cancer Sci 105: 370-388, 2014.
101. Iyama T and Wilson Iii DM: DNA repair mechanisms in dividing and non-dividing cells. DNA Repair 12: 620-636, 2013.